Cell membrane blebbing, chromatin condensation, genomic DNA fragmentation, and the exposure of particular phagocytosis signaling molecules on the cell surface are just a few of the distinctive morphological and biochemical features of the cell death process known as apoptosis. Apoptosis-initiated cell death is distinct from necrosis-induced cell death. Apoptotic death, in contrast, is silent and orderly. Necrotic cells are typically recognized as a danger signal by the immune system, which causes inflammation.
There are two main methods for inducing apoptotic cell death: The intrinsic pathway, also known as the Bcl-2-regulated or mitochondrial pathway, is strictly regulated by the BCL-2 family of proteins and is activated by a variety of developmental cues or cytotoxic insults, such as viral infection, DNA damage, and growth-factor deprivation.The tumor necrosis factor (TNF) receptor family members, such as Fas or TNF receptor-1 (TNFR1), which contain an intracellular death domain and can recruit and activate caspase-8 through the adaptor protein Fas-associated death domain (FADD; also known as MORT1) at the cell surface, are what initiate the extrinsic or death-receptor pathway. Without the involvement of the BCL-2 family, this recruitment results in the subsequent activation of downstream (effector) caspases like caspase-3, -6, or -7.
Numerous human diseases, including cancer, viral infections, autoimmune diseases, neurodegenerative disorders, and AIDS (acquired immunodeficiency syndrome), may be influenced by changes in cell survival, according to studies. Some of these diseases may not progress naturally unless specific therapies that change the apoptotic threshold are used.
| Structure | Cat No. | Product Name | CAS No. | Product Description |
|---|---|---|---|---|
|
V56414 | Lacidipine-13C8 (lacidipine-13C8; selepine-13C8) | 1261432-01-2 | Lacidipine-13C8 is the deuterium labelled form of Lacidipine. |
|
V51883 | Lacto-N-neotetraose (LNnT) | 13007-32-4 | Lacto-N-neotetraose (LNnT) is an endogenously produced metabolite. |
|
V34761 | Lactoferrin (17-41) (acetate) (Lactoferricin B acetate; Lfcin B acetate) | 2828433-30-1 | Lactoferrin 17-41 (Lactoferricin B) acetate corresponds to residues 17-41 of bovine lactoferrin and has anti-bacterial effect against a variety of microorganisms including Gram-positive (Gram+) and Gram-negative (Gram+) bacteria, viruses, protozoa and fungi. |
|
V54920 | Lacutoclax | 2291166-56-6 | Lacutoclax is a Bcl-2 inhibitor (antagonist) with anti-tumor activity. |
|
V84945 | LAH-1 | 3018150-68-7 | |
|
V34812 | Lapatinib ditosylate monohydrate (lapatinib ditosylate monohydrate; GW572016 ditosylate monohydrate; GW2016 ditosylate monohydrate) | 388082-78-8 | Lapatinib ditosylate monohydrate (GW572016 ditosylate monohydrate) is a potent inhibitor of ErbB-2 and EGFR tyrosine kinase domains, with IC50s of 10.2 and 9.8 nM for purified EGFR and ErbB-2, respectively. |
|
V56459 | Lapatinib-d4 (GW572016-d4; GW2016-d4) | 1184263-99-7 | Lapatinib-d4 is the deuterated form of Lapatinib . |
|
V51878 | LCS-1 | 41931-13-9 | LCS-1 is a superoxide dismutase 1 (SOD1) inhibitor. |
|
V51876 | LDC7559 | 2407782-01-6 | LDC7559 is an inhibitor (blocker/antagonist) of desmin D (GSDMD) and acts by inhibiting late stages of the neutrophil extracellular bactericidal network (NET). |
|
V35003 | LEESGGGLVQPGGSMK | 2096980-79-7 | LEESGGGLVQPGGSMK, a proteolytic peptide that is a component of Infliximab, can be used for quantitative analysis of Infliximab. |
|
V85863 | LEI-515 | ||
|
V29113 | Lenalidomide hemihydrate (Revlimid, CC 5013) | 847871-99-2 | Lenalidomidehemihydrate (Revlimid, CC-5013) is a derivative of thalidomide approved in the United States in 2005 for the treatment for myeloma and blood disorders called myelodysplastic syndromes. |
|
V51873 | Lenercept (p55TNF-R:Ig; Ro 45-2081; TNFR55-IgG1) | 156679-34-4 | Lenercept (Ro 45-2081) is a recombinant fusion protein consisting of a soluble TNF-receptor (p55) linked to the Fc portion of human IgG1. |
|
V54978 | Lepadin E | 444914-19-6 | Lepadin E is a ferroptosis inducer with significant cytotoxic effect and induces ferroptosis through the classic p53-SLC7A11-GPX4 pathway. |
|
V56453 | Lepadin H | 412328-25-7 | Lepadin H is a marine alkaloid and ferroptosis inducer. |
|
V54840 | Lepidozin G | 2869125-43-7 | Lepidozin G can suppress the growth of cancer cell lines with IC50s ranging from 4.2 ± 0.2 to 5.7 ± 0.5 μM. |
|
V55002 | Letolizumab (BMS-986004) | 1450981-87-9 | Letolizumab (BMS-986004) is a monoclonal antibody (mAb) targeting CD40L that was generated to express a mutant IgG1 lacking effector functions such as Fc binding and complement fixation. |
|
V51864 | Lexatumumab (HGS-ETR 2; ETR2-ST01; Anti-Human ERBB3 Recombinant Antibody) | 845816-02-6 | Lexatumumab (HGS-ETR 2) is a human agonist TRAIL receptor 2 (TRAIL-R2, DR5, APO-2) IgG4κ type monoclonal antibody (mAb). |
|
V54886 | LG308 | 1428341-65-4 | LG308 is a novel synthetic compound with antimicrotubule activity. |
|
V56406 | Licofelone-d6 (ML-3000-d6) | 1178549-81-9 | Licofelone-d6 is the deuterium labelled form of Licofelone. |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
